Department of Biosciences and Technology, School of Science and Environmental Studies, Dr. Vishwanath Karad MIT World Peace University, Pune, India.
Cancer Rep (Hoboken). 2024 Aug;7(8):e70005. doi: 10.1002/cnr2.70005.
Breast cancer is the most predominant and heterogeneous cancer in women. Moreover, breast cancer has a high prevalence to metastasize to distant organs, such as the brain, lungs, and bones. Patients with breast cancer metastasis to the bones have poor overall and relapse-free survival. Moreover, treatment using chemotherapy and immunotherapy is ineffective in preventing or reducing cancer metastasis.
Microorganisms residing in the gut and breast, termed as the resident microbiome, have a significant influence on the formation and progression of breast cancer. Recent studies have identified some microorganisms that induce breast cancer metastasis to the bone. These organisms utilize multiple mechanisms, including induction of epithelial-mesenchymal transition, steroid hormone metabolism, immune modification, bone remodeling, and secretion of microbial products that alter tumor microenvironment, and enhance propensity of breast cancer cells to metastasize. However, their involvement makes these microorganisms suitable as novel therapeutic targets. Thus, studies are underway to prevent and reduce breast cancer metastasis to distant organs, including the bone, using chemotherapeutic or immunotherapeutic drugs, along with probiotics, antibiotics or fecal microbiota transplantation.
The present review describes association of gut and breast microbiomes with bone metastases. We have elaborated on the mechanisms utilized by breast and gut microbiomes that induce breast cancer metastasis, especially to the bone. The review also highlights the current treatment options that may target both the microbiomes for preventing or reducing breast cancer metastases. Finally, we have specified the necessity of maintaining a diverse gut microbiome to prevent dysbiosis, which otherwise may induce breast carcinogenesis and metastasis especially to the bone. The review may facilitate more detailed investigations of the causal associations between these microbiomes and bone metastases. Moreover, the potential treatment options described in the review may promote discussions and research on the modes to improve survival of patients with breast cancer by targeting the gut and breast microbiomes.
乳腺癌是女性最常见和异质性的癌症。此外,乳腺癌有很高的转移到远处器官的倾向,如脑、肺和骨。患有乳腺癌转移到骨骼的患者整体和无复发生存率较差。此外,使用化疗和免疫疗法治疗不能预防或减少癌症转移。
居住在肠道和乳房中的微生物,称为常驻微生物组,对乳腺癌的形成和发展有重大影响。最近的研究已经确定了一些诱导乳腺癌转移到骨骼的微生物。这些生物利用多种机制,包括诱导上皮-间充质转化、类固醇激素代谢、免疫修饰、骨重塑和微生物产物的分泌,改变肿瘤微环境,并增强乳腺癌细胞转移的倾向。然而,它们的参与使这些微生物成为合适的新型治疗靶点。因此,正在研究使用化疗或免疫治疗药物以及益生菌、抗生素或粪便微生物群移植来预防和减少乳腺癌向远处器官(包括骨骼)的转移。
本综述描述了肠道和乳房微生物组与骨转移的关联。我们详细阐述了乳腺和肠道微生物组利用的机制,这些机制诱导乳腺癌转移,特别是转移到骨骼。该综述还强调了目前可能针对微生物组预防或减少乳腺癌转移的治疗选择。最后,我们指定了维持多样化肠道微生物组的必要性,以防止失调,否则可能会诱导乳腺癌发生和转移,特别是转移到骨骼。该综述可能有助于更详细地研究这些微生物组与骨骼转移之间的因果关系。此外,该综述中描述的潜在治疗选择可能会促进关于通过靶向肠道和乳房微生物组来提高乳腺癌患者生存率的讨论和研究。